ISHLT2024: Industry Symposia - Thursday
11 April, 2024 11:45 a.m. to 12:45 p.m. CEST
![ISHLT2024_Industry-Symposia_Thumbnail ISHLT2024 Industry Symposia](https://www.ishlt.org/images/default-source/ishlt2024/ishlt2024_industry-symposia_thumbnail.png?sfvrsn=78d961b0_1)
CareDx | CVRx | Natera | TransMedics
![Logo for CareDx](/images/default-source/sponsors/ishlt2024-caredx.png?sfvrsn=36a40b48_3)
Heart and Seek: A Case-Based Demonstration of Multi-Modal Molecular Tools’ Impact on Cardiac Transplant Surveillance
South Hall 2
CareDx
Heart and Seek: A Case-Based Demonstration of Multi-Modal Molecular Tools’ Impact on Cardiac Transplant Surveillance
Primary Core Therapy: Heart | Primary Practice Area: Cardiology
![Logo for CareDx](/images/default-source/sponsors/ishlt2024-caredx.png?sfvrsn=36a40b48_3)
The symposium will be an interactive case discussion of the clinical approach to molecular diagnostic interpretation in the context of early routine acute cellular rejection surveillance. The moderator will take the audience through two separate cases in which surveillance HeartCare testing is done on a monthly basis during the first-year post-transplant and the panelists will describe their preferred course of action as it relates to performance of biopsies, repeat testing or adjustment in immunosuppression.
Moderator
Yasbanoo Moayedi, MD, University Health Network, Toronto, ON Canada
Speakers
Shelley Hall, MD, FACC, FHFSA, FAST, Baylor University Medical Center, Dallas, TX USA
Farhana Latif, MD, New York Presbyterian Hospital, New York, NY USA
Jeffrey Teuteberg, MD,
Stanford University School of Medicine, Palo Alto, CA USA
![Logo for CVRx](/images/default-source/sponsors/ishlt2024-cvrx.png?sfvrsn=b1b31cf6_3)
Integrating Barostim into a Comprehensive Heart Failure Program
North Hall
CVRx
Integrating Barostim into a Comprehensive Heart Failure Program
Primary Core Therapy: Heart | Primary Practice Area: Cardiology
![Logo for CVRx](/images/default-source/sponsors/ishlt2024-cvrx.png?sfvrsn=b1b31cf6_3)
Expert faculty panel will discuss unmet needs with guideline-directed medical therapy, and review the latest in clinical data, mechanism of action, and patient selection for the use of Barostim in patients with HFrEF. Panel and audience discussions will include device selection in class II/III heart failure patients, patient selection and post-implant management, Barostim procedure and patient care pathways, and real world strategies for incorporating Barostim into a comprehensive heart failure program.
Moderator
Eugene Chung, MD, The Christ Hospital Network, Cincinnati, OH USA
Jan Schmitto, MD, Hannover Medical School, Hannover, Germany
Program
Challenges and Unmet Needs with GDMT in HFrEF
Richa Gupta, MD, MPH, MedStar Washington Hospital Center, Washington, DC USA
Beyond BeAT-HF: Real World Experience with Barostim
Pujan Patel, MD, Advent Health, Raleigh, NC USA
Integrating Barostim into a Comprehensive Heart Failure Program
Dmitry Yaranov, MD, Baptist Medical Group, Memphis, TN USA
![Logo for Natera](/images/default-source/sponsors/ishlt2024-natera.png?sfvrsn=f045d57b_3)
Challenges of Single Lung Transplant and the Value of dd-cfDNA
Panorama Hall
Natera
Challenges of Single Lung Transplant and the Value of dd-cfDNA
Primary Core Therapy: Lung | Primary Practice Area: Pulmonology
![Logo for Natera](/images/default-source/sponsors/ishlt2024-natera.png?sfvrsn=f045d57b_3)
There are inherent, increased risks and challenges associated with single lung transplantation over double lung. It is a procedure typically reserved for older, more frail recipients because of the shorter operating time and less complex nature of the surgery. Yet despite the less complex surgery, the mean survival rate of single lung transplant recipients is only 4.7 years, almost half that of double lung recipients. SLT recipients also have a higher risk of acute cellular rejection (ACR) and chronic lung allograft dysfunction (CLAD). Standard of care to monitor and assess the health of the transplanted lung is through invasive transbronchial biopsy procedures (TBBx). Serious complication rates range depending on the center and study from 7- 46% in SLT recipients. This highlights an even greater need in the single lung population for noninvasive surveillance options. Donor derived cell free DNA (dd-cfDNA) has been validated in single and double lung transplants with emerging data in support of clinical utility. This symposium will focus on the recent data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.
Moderator
David Ross, MD, Natera, Austin, TX USA
Program
Single Lung Transplant Review of Indications / Challenges
Reinaldo Rampollo, MD, Cedars-Sinai, Los Angeles, CA USA
SLAM Data Presentation
Ambalavanan Arunachalam, MD, Northwestern Memorial Hospital, Chicago, IL USA
![Logo for TransMedics](/images/default-source/sponsors/ishlt2024-transmedics.png?sfvrsn=ba521821_3)
TransMedics National OCS Program (NOP) – Transforming the Standard of Care and Delivering Excellent Outcomes
South Hall 1
TransMedics
![Logo for TransMedics](/images/default-source/sponsors/ishlt2024-transmedics.png?sfvrsn=ba521821_3)
TransMedics National OCS Program (NOP) – Transforming the Standard of Care and Delivering Excellent Outcomes
Primary Core Therapy: Heart | Primary Practice Area: Cardiothoracic Surgery
This session will highlight clinical outcomes, the national program and logistics network related to the organ care system for heart & lung.
Moderators
David D'Alessandro, MD, Massachusetts General Hospital, Boston, MA USA
Brandon Guenthart, MD, Stanford University, Palo Alto, CA USA
Program
Second Annual Report from The OCS Heart Perfusion (OHP) Registry in the USA – Post-Approval Clinical Experience
Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT USA
OCS Lung Use – Delivering Program Volume Growth and Improved Transplant Outcomes
Gabriel Loor, MD, Baylor College of Medicine, Houston, TX USA
Significant Reduction in PGD Incidence Associated with OCS DCD Heart Transplant Recipients In Real World Clinical Experience – Potential NOP Impact on Outcomes
Mani Daneshmand, MD, Emory University, Atlanta, GA USA
Cardioprotective Effect of OCS Perfusion in 4 and 6 hours Preservation – Histopathological Results of Randomized Controlled Study
Anthony Demitris, MD, University of Pittsburgh Medical Center, Pittsburgh, PA USA
Farhan Zafar, MD, TransMedics, Inc., Boston, MA USA
Second Year Performance Review of The US National OCS Program (NOP) for Cardiothoracic Transplants
Waleed Hassanein, MD, TransMedics, Inc., Boston, MA USA